Condensed Consolidated Statements of Operations (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Revenues:
Research and development programs	$ 2,680	$ 9,560
Product revenues	4,000	3,996
Total revenues	6,680	13,556
Costs and operating expenses:
Cost of product revenue	1,454	1,246
Research and development	13,720	15,361
Sales, general and administrative	14,866	14,056
Total costs and operating expenses	30,040	30,663
Loss from operations	(23,360)	(17,107)
Other income (expense):
Interest and other income, net	348	546
Interest expense	(1,871)	(219)
Loss from equity method investment	(959)
Gain from change in fair value of warrant liability	54
Loss from change in fair value of derivative liability	(737)
Total other income (expense)	(3,165)	327
Net loss	$ (26,525)	$ (16,780)
Net loss per share, basic and diluted	$ (0.43)	$ (0.28)
Weighted average number of common shares used in loss per share computation, basic and diluted	61,542,509	60,101,176